| | 技 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 000524 | 岭南控 | 2.68 | 2.58 | 11.95 | 12.25 | 2.51 | | | 股 | | | | | | | 300808 | 久量股 | 2.72 | 1.38 | 28.36 | 29.05 | 2.44 | | | 份 | | | | | | | 920221 | 易实精 | 7.29 | 12.77 | 17.67 | 18.10 | 2.41 | | | 密 | | | | | | | 000428 | 华天酒 | 4.27 | 7.26 | 3.34 | 3.42 | 2.38 | | | 店 | | | | | | | 688090 | 瑞松科 | 2.61 | 1.45 | 34.18 | 34.99 | 2.37 | | | 技 | | | | | | | 600738 | 丽尚国 | 6.18 | 10.33 | 5.21 | 5.33 | 2.35 | | | 潮 | | | | | | | 603900 | 莱绅通 | 2.8 ...

| | 股 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 002972 | 科安达 | 3.97 | 3.13 | 11.55 | 11.79 | 2.1 1 | | 000428 | 华天酒 | 3.96 | 6.46 | 3.34 | 3.41 | 2.08 | | | 店 | | | | | | | 603088 | 宁波精 | 6.59 | 5.57 | 10.00 | 10.19 | 1.85 | | | 达 | | | | | | | 300565 | 科信技 术 | 4.08 | 10.53 | 12.28 | 12.50 | 1.80 | | 002590 | | | | | | | | | 万安科 技 | 1.99 | 4.25 | 13.60 | 13.82 | 1.65 | | 688266 | 泽璟制 药 | 1.87 | 0.60 | 97.28 | 98.85 | 1.61 | | 600130 | *ST波导 | 1.32 | 1.17 | 3.77 | 3.83 | 1.54 | | 605337 | 李子园 ...

这种双线思维使其在2019-2021年行业普遍重仓医疗服务时保持独立判断，并在2022年市场回调中有效控制回撤。具体而言，明线策略重点布局具有"星辰 大海"特质的产业方向，如创新药、基因编辑等前沿领域。 来源|财富独角兽 2025年以来，A股市场整体呈现震荡上行态势。在此背景下，医药生物主题基金的表现尤为亮眼，成为全市场中最耀眼的板块之一。上半年数据显示，在 股票型基金涨幅前十榜单中，医药生物主题基金占据了绝大多数席位。 笔者发现，金笑非作为鹏华基金自主培养的中生代基金经理代表，其管理的鹏华医药科技股票与鹏华创新升级混合等产品业绩表现尤为亮眼。他独创 的"明暗双线共振"框架，也正是在这一框架的指引下，金笑非成功规避了机构过度拥挤的板块。不过，这种强势表现并非偶然，而是多重因素共同作用的 结果。 01 文|天峰 曾低位买入百济神州 宝盈金笑非最佳任期回报239.59% 据天天基金网显示，金笑非于2012年7月加盟鹏华基金管理有限公司,从事行业研究工作,历任研究部基金经理助理/高级研究员,现任权益投资二部副总经理/ 基金经理。截至目前金笑非累计任职时间9年又174天，现任基金资产总规模53.75亿元，在管基金最佳 ...

| | | | 12月15日目标价涨幅排名 | | | | --- | --- | --- | --- | --- | --- | | 证券代码 | 证券名称 | 机构 | 最新评级 | 雷宫目牺价 | 目标涨幅 | | | | | | (元) | (%) | | 688266 | 泽揚制药 | 中信证券 | 买入 | 135.00 | 35.00 | | 300181 | 佐力药业 | 国投证券 | 买入 | 23.12 | 34.58 | | 300083 | 创世纪 | 中国国际金融 | 跑赢行业 | 11.30 | 27.40 | | 000876 | 新希望 | 国泰海通证券 | 增持 | 11.27 | 24.39 | | 600729 | 重庆百货 | 中信证券 | 买入 | 32.00 | 23.74 | | 002595 | 蒙迈科技 | 中国国际金融 | 跑赢行业 | 97.00 | 15.64 | | | | | 日期:12月15日,南财投研通×南财快讯制图 | | | 从券商推荐家数来看，12月15日有21家上市公司得到券商推荐，其中佐力药业获得5家推荐，天地科 技、常宝股份等均获得1 ...

首次覆盖方面，12月15日券商共给出了7次首次覆盖，其中常宝股份获得招商证券给予"增持"评级，创 世纪获得中国国际金融给予"跑赢行业"评级，上汽集团获得爱建证券给予"买入"评级，屹唐股份、和林 微纳获得东北证券分别给予"增持""买入"评级。 | | | 7家最新被首次覆盖的公司 | | | | --- | --- | --- | --- | --- | | 证券代码 | 证券名称 | 机构 | 最新评级 | 行业 | | 002478 | 常享股份 | 招商证券 | 増持 | 特钢 | | 300083 | 创世纪 | 中国国际金融 | 跑赢行业 | 自动化设备 | | 600104 | 上汽集团 | 爱建证券 | 买人 | 乘用车 | | 688729 | 吃唐股份 | 东北证券 | 增持 | # | | 688661 | 和林微纳 | 东北证券 | 买人 | #9体 | | 002409 | 雅克科技 | 东北证券 | 买人 | #s体 | | 688082 | 奥上米能 | 东北证券 | 买入 | # | | | | 日期:12月15日,南财投研通×南财快讯制图 | | | （文章来源：21世纪经济报道 ...

南方财经12月16日电，南财投研通数据显示，12月15日，券商给予上市公司目标价共6次，按最新收盘 价计算，目标价涨幅排名居前的公司有泽璟制药、佐力药业、创世纪，目标价涨幅分别为35.00%、 34.58%、27.40%，分别属于化学制药、中药、自动化设备行业。从券商推荐家数来看，12月15日有21 家上市公司得到券商推荐，其中佐力药业获得5家推荐，天地科技、常宝股份等均获得1家推荐。查看原 文：21股获推荐，泽璟制药、佐力药业目标价涨幅超30%丨券商评级观察刚刚 ...

证券之星消息，12月15日，医疗健康R（480016）指数报收于7247.38点，跌1.42%，成交212.07亿元，换 手率0.7%。当日该指数成份股中，上涨的有12家，同仁堂以2.38%的涨幅领涨，下跌的有35家，泽璟制 药以8.6%的跌幅领跌。 医疗健康R（480016）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sh688266 | 演唱制药 | -- | 100.00 | -8.60% | 264.71 | 医药生物 | | sh688336 | 三生国健 | -- | 60.70 | -5.83% | 374.39 | 医药生物 | | sh688192 | 迪哲医药 | -- | 58.54 | -5.73% | 269.98 | 医药生物 | | sh688520 | 神州细胞 | | 44.65 | -4.08% C | 198.84 | 医药生物 | | sz002294 | 信立泰 | -- | 56.50 | -3 ...

Group 1 - The report highlights the recent performance of various industries, with notable gains in sectors such as non-ferrous metals, electronics, and power equipment, while retail and real estate sectors faced declines [1][1][1] - The central economic work conference emphasized the importance of technological breakthroughs and supply-demand optimization, indicating a shift towards quality improvement in economic growth [11][12][19] - The commercial aerospace sector is experiencing significant growth, with the establishment of a dedicated regulatory body and a notable increase in the commercial aerospace index, which has risen by 46.52% since April 7 [47][48] Group 2 - The report indicates a seasonal recovery in social financing, with November seeing an increase of 24,885 billion yuan, driven primarily by government bond issuance [4][7] - The credit environment is showing signs of marginal improvement, particularly in corporate loans, which increased by 6,100 billion yuan in November, reflecting a recovery in demand [5][6] - The report notes that the retail sector is undergoing a transformation, with a focus on quality, as highlighted by the Ministry of Commerce's emphasis on retail quality upgrades [1][1][1] Group 3 - The report discusses the rising interest in inquiry transfers, which have seen a significant increase in both project numbers and transfer scale, indicating a growing trend in the market [51][52] - The technology sector is expected to remain a key focus, with upcoming events such as the Volcano Engine FORCE conference anticipated to showcase advancements in AI and cloud services [56]

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

中国上海石门一路 288 号兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 君合律师事务所上海分所 关于苏州泽璟生物制药股份有限公司 2025 年第一次临时股东会的 法律意见书 苏州泽璟生物制药股份有限公司： 君合律师事务所上海分所（以下简称"本所"）接受苏州泽璟生物制药股份 有限公司（以下简称"公司"或"泽璟制药"）的委托，指派本所经办律师出席 了公司 2025 年第一次临时股东会（以下简称"本次股东会"）的现场会议。现 本所根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 会规则》等中国（仅为本法律意见书之目的，"中国"不包括香港特别行政区、 澳门特别行政区及台湾地区）现行法律、法规和规范性文件以及《苏州泽璟生物 制药股份有限公司章程》（以下简称"《公司章程》"）、公司股东会议事规则 的有关规定，就本次股东会有关事宜出具本法律意见书。 为出具本法律意见书，本所审查了公司提供的有关文件及其复印件，核对了 其中相关文件的原件，并取得公司向本所作出的如下保证：公司已向本 ...